Market Tracker

02/05 5:16pm ET

Merck & Co Inc (NYSE:MRK)

49.38
Delayed Data
As of Feb 05
 +0.79 / +1.63%
Today’s Change
45.69
Today|||52-Week Range
61.70
-6.51%
Year-to-Date
Last Week's Best Healthcare ETF
1:15pm / MotleyFool.com
Should You Buy Merck (MRK) Ahead of Earnings?
Feb 02 / Zacks.com
Grading Gilead Sciences' Performance in 2015
9:41am / MotleyFool.com
Stocking Up on Cheap Biotech Stocks
Feb 02 / TheStreet.com
1 Company Gilead Sciences Should Consider Buying Right Now
9:41am / MotleyFool.com
Will Merck (MRK) Keep the Earnings Streak Alive in Q4?
Feb 01 / Zacks.com
ImmunoGen/Merck Collaborate for Ovarian Cancer Study
Feb 05 / Zacks.com
Is Alexion (ALXN) Likely to Disappoint this Earnings Season?
Feb 01 / Zacks.com
Amgen's Blincyto and Repatha Positive in Phase III Studies
Feb 05 / Zacks.com
3 Numbers That Matter When Merck Reports Its Fourth-Quarter Results
Feb 01 / MotleyFool.com
Gilead Sciences 2016 Guidance: Sandbagging Wall Street Again?
Feb 05 / MotleyFool.com
GW Pharmaceuticals (GWPH): What Awaits in Q1 Earnings?
Feb 01 / Zacks.com
Dow 30 Stock Roundup: Microsoft, Exxon Beat on Earnings, Chevron Incurs Loss
Feb 05 / Zacks.com
Investor calls for big pharma to slim down grow louder
Feb 01 / FT.com
String of Q4 Earnings Beat Fails to Revive Pharma ETFs
Feb 05 / Zacks.com
Jim Cramer's Long-Term View on Health Care Stocks
Feb 01 / TheStreet.com
5 Stocks We're Buying Again
Feb 05 / MotleyFool.com
Will 2016 Be Merck & Co. Inc.'s Best Year Yet?
Feb 01 / MotleyFool.com
2 Numbers in Merck's 4th-Quarter Report That Have Investors Worried
Feb 04 / MotleyFool.com
Biotech ETFs Hit 52-Week Lows: Time to Buy?
Feb 01 / Zacks.com
Company News for February 04, 2016
Feb 04 / Zacks.com
Rally Hobbled As Ugly China Reality Replaces Japan NIRP Euphoria; Oil Rebound Fizzles
Feb 01 / Investing Channel
Hedge fund pioneer is force behind hotly tipped biotech companies
Feb 04 / FT.com
Gilead risks becoming victim of its own success
Jan 31 / FT.com
Merk (MRK) Earnings Report: Q4 2015 Conference Call Transcript
Feb 03 / TheStreet.com
Merck's HCV Drug Zepatier Gets FDA Nod; Sets Lower Price
Jan 29 / Zacks.com
International Growth Propels Gilead Sciences Inc.'s Solid Q4 Results
Feb 03 / MotleyFool.com
Instant Analysis: Gilead Sciences Inc.'s Longtime CEO Steps Down
Jan 29 / MotleyFool.com
3 Stocks Pulling The Drugs Industry Downward
Feb 03 / TheStreet.com
Why is Gilead (GILD) Stock Falling Today?
Jan 29 / Zacks.com
Merck Tops on Q4 Earnings, Revenue Outlook Falls Short
Feb 03 / Zacks.com
Will Pfizer (PFE) Keep the Earnings Streak Alive in Q4?
Jan 29 / Zacks.com
Stocks Slump as Services Sector Slows to 2014 Low
Feb 03 / TheStreet.com
Merck launches hepatitis C drug price war
Jan 29 / FT.com
Gilead (GILD) Beats Q4 Earnings Estimates, Gives 2016 View
Feb 03 / Zacks.com
Instant Analysis: Can Merck Make Waves In the Crowded Hepatitis C Space?
Jan 29 / MotleyFool.com
Merck (MRK) Stock Declines in Pre-Market Trading on Q4 Revenue Miss
Feb 03 / TheStreet.com
Merck's Hepatitis C Doublet Wins FDA Approval and Unveils Its Secret Weapon
Jan 29 / MotleyFool.com
Merck's (MRK) Q4 Earnings Beat Estimates
Feb 03 / Zacks.com
CDXS and LOGI are Aggressive Growth Stocks
Jan 28 / Zacks.com
Frontrunning: February 3
Feb 03 / Investing Channel
Johnson & Johnson's Newest Billion-Dollar Blockbuster
Jan 28 / MotleyFool.com
Why Medivation, Inc. Shares Crashed 32% in January
Feb 03 / MotleyFool.com
Affimed & Merck Ink Deal for AFM13-Keytruda Combination
Jan 27 / Zacks.com
Can Perrigo (PRGO) Beat Q4 Earnings on Generic Sales?
Feb 02 / Zacks.com
England backs biosimilar challenger to Merck blockbuster
Jan 26 / FT.com
Why Gilead Sciences Shares Tumbled 18% in January
Feb 02 / MotleyFool.com
A Billion-Dollar Drug? Maybe. But Lilly Will Have to Overcome This Roadblock First
Jan 26 / MotleyFool.com
Merck (MRK) Stock Declines Before Wednesday's Earnings
Feb 02 / TheStreet.com
Forget Pfizer Inc.: Here Are 2 Better Dividend Stocks
Jan 26 / MotleyFool.com